Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08KTT
|
||||
| Former ID |
DAP000614
|
||||
| Drug Name |
Sildenafil
|
||||
| Synonyms |
Aphrodil; VIA; Aphrodil (TN); Revatio (TN); Sildenafil (INN); Sildenafil [INN:BAN]; UK-92480; Viagra (TN); UK-92,480-10; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate; 5-(2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; 5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (Sildenafil or Viagra); 5-[2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one(Sildenafil); 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-(ethyloxy)-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antiimpotence Agents
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H30N6O4S
|
||||
| InChI |
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
|
||||
| InChIKey |
BNRNXUUZRGQAQC-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 139755-83-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9468, 585744, 832888, 4075716, 4368414, 4980084, 7980598, 8153203, 11342069, 11362252, 11364449, 11367011, 11369573, 11373023, 11374191, 11377735, 11485511, 11487654, 11489464, 11491707, 11492401, 11495369, 11528697, 14834479, 14883184, 26612617, 26680877, 26748898, 26748899, 29215463, 29224269, 46393303, 46393579, 46394222, 46508371, 46514731, 47810856, 48259349, 48416538, 50085897, 50416042, 53786977, 56313704, 56322606, 57322656, 61212546, 81040866, 85248200, 85788522, 89736128
|
||||
| SuperDrug ATC ID |
G04BE03
|
||||
| SuperDrug CAS ID |
cas=139755832
|
||||
| Target and Pathway | |||||
| Target(s) | CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [535598], [535643], [535660], [537507] | |
| KEGG Pathway | Purine metabolism | ||||
| cGMP-PKG signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | cGMP effects | ||||
| References | |||||
| Ref 467986 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743). | ||||
| Ref 536497 | Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88. | ||||
| Ref 535598 | Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002 Sep;60(2 Suppl 2):49-57. | ||||
| Ref 535643 | Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002 Dec;14(6):466-71. | ||||
| Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
| Ref 537507 | cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Jun 22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.